Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05935384 · ClinicalTrials.gov registry record
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
A clinical trial of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Guardant Health.
- Recruiting
- Registry status
- 470
- Enrollment target
- 1
- Study location
NCT05935384: Recruiting study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Guardant Health.
NCT05935384 is a study of Breast Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by Guardant Health. The registered enrollment target is 470 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05935384, a study of Breast Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Guardant Health.
- RECRUITING
- Registry status
- 470 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors. It is necessary to collect clinical data points and treatment outcomes in order to demonstrate clinical validity for longitudinal monitoring with ctDNA and correlation of ctDNA dynamics with therapeutic response, as evaluated by standard methods, including RECIST 1.1 and CT scan measurements.
Primary Outcome
The Primary Endpoint, sensitivity of ctDNA to detect disease progression, will be evaluated from all eligible subjects within the primary study cohorts (breast cancer, NSCLC, or CRC)
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Guardant360
Study Locations (1)
Illinois
- Orchard Healthcare Research Inc. - Skokie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2030-12-30 |
What NCT05935384 shows while recruiting
NCT05935384 is an observational study that tracks outcomes without assigning an intervention. The registered 470 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (83% lower).
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Guardant360 is the first listed.
NCT05935384 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05935384 about?
NCT05935384 is a clinical study titled "SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation". The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors. It is necessary to collect clinical data points and treatment outcom...
What is the current status of trial NCT05935384?
This trial is currently recruiting. The enrollment target is 470 participants. The study started on 2023-10-25. Estimated completion is 2030-12-30.
What conditions does trial NCT05935384 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer.
What interventions are being tested in trial NCT05935384?
The interventions under investigation include: Guardant360 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05935384?
This trial is sponsored by Guardant Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05935384 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05935384's enrollment target sits among peer trials
470 209th of 1224 higher than 1,015 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05256940 · 470 participants · NA
Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
- NCT05458219 · 470 participants · Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- NCT05850689 · 470 participants · Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- NCT06149286 · 470 participants · Phase 3
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI